Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ATM loss |
| Therapy | Niraparib |
| Indication/Tumor Type | pancreatic ductal adenocarcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ATM loss | pancreatic ductal adenocarcinoma | predicted - sensitive | Niraparib | Case Reports/Case Series | Actionable | In a Phase II trial, Zejula (niraparib) treatment in metastatic pancreatic ductal adenocarcinoma patients harboring mutations in ATM (n=14), BRCA1 (n=2), BRCA2 (n=10), CHEK2 (n=4), or PALB2 (n=3) resulted in a 6-month progression-free survival rate of 25%, objective response rate of 14% (4/32, 2 complete, 2 partial responses), and median overall survival of 10.2 mo in the overall cohort, and prolonged response greater than 1 year in 3 patients with biallelic ATM loss (PMID: 41686836; NCT03601923). | 41686836 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (41686836) | A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. | Full reference... |